Ovarian cancer is the fourth-leading cause of cancer deaths
among women in the U.S. When someone is diagnosed with ovarian cancer, they are
usually in the advanced stages of the disease and treatment is not nearly as
effective as it would be if it had been discovered earlier. Avant Diagnostics,
Inc. (OTCQB: AVDX) is a medical diagnostic technology company that specializes
in large panel biomarker screening. The company’s first test, OvaDx®, is a
sophisticated microarray-based test designed to detect pre-symptomatic ovarian
cancer by measuring the activation of the immune system in blood samples in
response to early stage ovarian tumor cell development.
In clinical development, OvaDx has indicated high
sensitivity and specificity for all types and stages of ovarian cancer,
including stage IA-IV borderline serous, clear cell, endometrioid, mixed
epithelial, mucinous, serous and ovarian adenocarcinoma. Upon FDA approval,
Avant plans to offer its diagnostic product as an elective test for women
seeking greater wellness, as well as those in the elevated risk category for
ovarian cancer.
In a recent Time magazine article (http://dtn.fm/sv0Pa),
there is a great comparison study done on a largely ineffective technique
currently used for early detection of ovarian cancer. A blood test, called
CA-125, can pick up signs of tumors in the ovaries, but it’s not very specific
or sensitive for these growths. CA-125 levels can rise not just because of
ovarian tumors, but during menstruation and pregnancy as well. That may explain
why the test only picks up 60% to 65% of cancers.
OvaDx is expected to be used by doctors to advance the forefront
of ovarian cancer treatment, promoting the utilization of improved surgical
options and more effective chemotherapies by serving as a supplement to
existing tests, such as CA-125, OVA1® and transvaginal ultrasound. In this way,
Avant’s innovative product will promote earlier diagnoses and, as a result,
improved survival rates for patients with ovarian cancer.
According to another Time magazine article
(http://dtn.fm/J1Vwa), the traditional treatment for ovarian cancer is surgery
followed by rounds of monthly chemotherapy. The treatment is effective, but
there is growing evidence that exposing tumors to such high dose toxic agents
at one time is effective in killing cancer cells in the short term, but may
encourage chemo-resistant cells to flourish over time.
The common theme here is that early identification of
problems (ovarian cancer in this case) is essential in order to take full
advantage of currently available treatment options. Cancer is just like the
‘The Blob’ from the classic 1950’s movie and the 1980’s remake. If people would
have properly identified the Blob/cancer earlier, it could have been
frozen/treated and stored away so that people could have gone on with their
daily lives without worry and pain.
For more information, visit the company website at
www.avantdiagnostics.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment